Trial Profile
Effect of RSR13 [efaproxiral] on T2 and T2* cranial MRI [magnetic resonance imaging] images: an imaging companion study to NABTT 9806.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs Efaproxiral (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 18 Oct 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Mar 2007 New trial record.